BRILIQUE® (ticagrelor)

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†1

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1

BRILIQUE (ticagrelor) 90mg twice daily  in combination with  acetylsalicylic acid (ASA) is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg twice daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment

 

References

 
  1. BRILIQUE (ticagrelor) Summary of Product Characteristics. Available at: http/www.medicines.org.uk [accessed June 2019].
  2. Prasugrel Summary of Product Characteristics. Available from http://www.medicines.org.uk [accessed March 2019].
  3. Sanofi. Plavix Summary of Product Characteristics. Available from http://www.medicines.org.uk [accessed March 2019].
  4. Wallentin L et al. N Engl J Med 2009; 361: 1045-1057.
  5. Lindholm D et al. Eur Heart J 2014; 35, 2083-2093.
  6. ©NICE [2011] Ticagrelor for the treatment of acute coronary syndromes. Available from: www.nice.org.uk/guidance/TA236c[accessed December 2018]. All rights reserved. Subject to Notice of rights.
  7. Wallentin L et al. N Engl J Med 2009; 361: 1045-1057. Supplementary information.
  8.  BRILIQUE 90mg. Orodispersible Tablets Summary of Product Characteristics. June 2019. https://www.medicines.org.uk/emc/medicine/33506. Accessed June 2019.
  9. Bonaca MP et al. Am Heart J 2014; 167(4):437-444.
  10. ©NICE [2016]  Ticagrelor for preventing atherothrombotic events after myocardial Infarction. Available from: www.nice.org.uk/guidance/ta420 [accessed March 2019]. All rights reserved. Subject to Notice of rights.
  11. Teng R, Carlson G, Hsia J. An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. International journal of clinical pharmacology and therapeutics. 2015 Feb;53(2):182.
  12. Scottish Medicines Consortium. Ticagrelor 90 mg film-coated tablets (Brilique) .SMC No. (699/11). Available at: https://www.scottishmedicines.org.uk/SMC_Advice/Advice/699_11_ticagrelor_Brilique/ticagrelor_Brilique (accessed March 2019).
  13. Valgimigli M et al. Eur Heart J 2017. doi.10.1093/eurheartj/ehx419.
  14. Ibanez B et al. Eur Heart J 2017. doi:10.1093/eurheartj/ehx393.
  15. Bonaca MP et al. N Engl J Med 2015; 372:1791-1800. 
  16. Wiviott SD et al. N Engl J med 2007;357: 2001-2015.
  17. Jernberg T et al. Eur Heart J 2015;36(19): 1163-1170.
  18. Ozcan C et al. Eur Heart J Cardiovasc Pharmacother 2017. doi: 10.1093/ehjcvp/pvx009
  19. Timmis A et al. BMJ 2016;353:i3163.
  20. Alexopoulos D et al. Circ Cardiovasc Interv 2013;6: 277-283.
  21. Armstrong D et al. J Cardiovasc Pharmacol Ther 2014; 19: 209-219.
  22. Verenhorst C et al. J AM Heart Assoc 2018;7:e007174.
  23. James S et al. Am Heart J 2009;157: 599-605.
  24. Wallentin L. Eur Heart J 2009;361: 1045-1057
  25. Sahlen A et al. Eur Heart J 2016;37(44):3335-3342.
  26. Sahlen A et al. Eur Heart J 2016;37(44):3335-3342 (supplementary information). https://academic.oup.corn/eurheartj/article/37/44/3335/2733196.Accessed March 2019.
  27. Bonaca MP et al. JAMA Cardiol 2016;1(4): 425-432.doi:10.1001/jamacardio.2016.1017.
  28. Bonaca MP et al. N Engl J Med 2015;372: 1791-1800. Supplementary information.
  29. Bonello L et al. J Am Coll Cardiol;2014;63: 872-877.
  30. Bonaca MP et al. Eur Heart J 2016;37(14):1133-1142.
  31. Bonaca MP et al. Eur Heart J 2016;37(14):1133-1142. (supplementary information). https://academic.oup.com/eurheartj/article/37/14/1133/2466069. Accessed March 2019.
  32. Dellborg M et al. European Society for Cardiology Congress, Barcelona 2017. Poster presentation 3670.
  33. Bonaca MP et al. J Am Coll Cardiol 2017;70(11):1368-1375.
  34. AstraZeneca. Data on File. BRIL/032/OCT2017.
  35. Cannon CP et al. N Engl J Med 2001;344(25):1879-1887.
  36. Piepoli MF et al. Eur Heart J 2016;37(29):2315-2381.
  37. Schömig A. N Engl J Med 2009;361: 1108-1111.
  38. Gurbel PA et al. Circulation 2009;120: 2577-2585.
  39. Wallentin L et al. Lancet 2010;376:1320-1328.
  40. Mega JL et al. N Engl J Med 2009;360(4):354-362.
  41. Clopidogrel Summary of Product Characteristics. Available at http://www.medicines.org.uk [accessed March 2019].
  42. Van Giezen JJJ et al. J Thromb Haemost 2009;7: 1556-1565.
  43. Husted S et al. Eur Heart J 2006;27: 1038-1047.
  44. AstraZeneca. Data on File. BRIL/002/AUG2017
  45. James SK et al., BMJ. 2011;342:d3527
  46. Cannon CP et al., Lancet. 2010;375:283-293
  47. AstraZeneca. Data on File. BRIL-037-FEB2019
  48. Mehran R et al. Lancet 2013; 382: 1714–22 

 

GB -18187 - August 2019